New Recruiting Trial: A Study Investigating Intravenous Human Normal Immune Globulin (IGIV) 10% in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

WHY IT MATTERS

This Phase 3 trial is now actively recruiting patients with CIDP — if you have confirmed CIDP diagnosis, you may be eligible to access a potential new treatment option before it becomes widely available.

Researchers are testing a medicine called IGIV 10% to see if it helps people with CIDP, a rare nerve disease that causes weakness and numbness, usually in the legs and feet. IGIV is made from antibodies collected from donated blood. This is a Phase 3 trial, which means the medicine has already been tested in earlier studies and now doctors want to confirm it works well and is safe.

NCT ID: NCT06752356 Title: A Study Investigating Intravenous Human Normal Immune Globulin (IGIV) 10% in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Status: RECRUITING Phase: PHASE3 Sponsor: Kedrion S.p.A. Start date: 2026-04-01 URL: https://clinicaltrials.gov/study/NCT06752356 Source: UniteRare clinical trials database

YOU CAN ACT ON THIS

Check the trial website (clinicaltrials.gov/study/NCT06752356) to see if there's a recruiting site near you and contact them to learn about eligibility requirements.